{"title":"成人支气管扩张症患者支气管扩张症健康问卷的心理计量学验证和最小临床意义差异的确定。","authors":"Jin-Fu Xu, Surinder S Birring, Yuan-Yuan Li, Ming-Xin Shi, Hai-Wen Lu, Shuyi Gu, Jie-Ming Qu, Yong-Hua Gao, Wei-Jie Guan, Nan-Shan Zhong","doi":"10.1513/AnnalsATS.202407-751OC","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>The Bronchiectasis Health Questionnaire (BHQ) is a concise, self-administered and disease-specific instrument for measuring health-related quality-of-life (HRQoL) in bronchiectasis.</p><p><strong>Objectives: </strong>To investigate the psychometric properties of simplified Mandarin BHQ and determine the minimum clinically important difference (MCID) as a reliable clinical endpoint for assessing the efficacy of bronchiectasis treatments.</p><p><strong>Methods: </strong>A longitudinal, randomized controlled trial cohort of 357 patients treated with tobramycin inhalation solution or saline inhalation for Pseudomonas aeruginosa infection, along with a cross-sectional observational cohort including 436 patients with bronchiectasis were analyzed. Psychometric analyses encompassed convergent validity, known-groups validity, internal consistency, test-retest reliability, and responsiveness. Both anchor-based and distribution-based approaches were utilized to calculate the MCID for therapeutic response.</p><p><strong>Results: </strong>There were significant positive correlations between BHQ scores and the Quality of Life - Bronchiectasis Respiratory Symptom Scale (QoL-B-RSS), with correlation coefficient 0.698 in the trial cohort and 0.567 in the clinical cohort (both P<0.0001). Known-groups validity indicated significant differences in BHQ scores stratified by baseline Bronchiectasis Severity Index. BHQ scores correlated modestly with both FEV1% predicted and exacerbation frequency within the previous year. In the trial cohort, BHQ demonstrated excellent internal consistency (Cronbach's alpha: 0.893) and test-retest reliability (intraclass correlation coefficient: 0.853). An 8-point improvement in QoL-B-RSS corresponded to a mean increase of 5.49 points in BHQ scores after 4-week treatment. The MCID for BHQ was consistently 3 points.</p><p><strong>Conclusions: </strong>The BHQ (MCID: 3 points) represents a clinically meaningful tool for evaluating therapeutic intervention outcomes and patient-centered outcomes in patients with bronchiectasis.</p>","PeriodicalId":93876,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Psychometric Validation and Determination of the Minimal Clinically Important Difference for Bronchiectasis Health Questionnaire in Adults with Bronchiectasis.\",\"authors\":\"Jin-Fu Xu, Surinder S Birring, Yuan-Yuan Li, Ming-Xin Shi, Hai-Wen Lu, Shuyi Gu, Jie-Ming Qu, Yong-Hua Gao, Wei-Jie Guan, Nan-Shan Zhong\",\"doi\":\"10.1513/AnnalsATS.202407-751OC\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Rationale: </strong>The Bronchiectasis Health Questionnaire (BHQ) is a concise, self-administered and disease-specific instrument for measuring health-related quality-of-life (HRQoL) in bronchiectasis.</p><p><strong>Objectives: </strong>To investigate the psychometric properties of simplified Mandarin BHQ and determine the minimum clinically important difference (MCID) as a reliable clinical endpoint for assessing the efficacy of bronchiectasis treatments.</p><p><strong>Methods: </strong>A longitudinal, randomized controlled trial cohort of 357 patients treated with tobramycin inhalation solution or saline inhalation for Pseudomonas aeruginosa infection, along with a cross-sectional observational cohort including 436 patients with bronchiectasis were analyzed. Psychometric analyses encompassed convergent validity, known-groups validity, internal consistency, test-retest reliability, and responsiveness. Both anchor-based and distribution-based approaches were utilized to calculate the MCID for therapeutic response.</p><p><strong>Results: </strong>There were significant positive correlations between BHQ scores and the Quality of Life - Bronchiectasis Respiratory Symptom Scale (QoL-B-RSS), with correlation coefficient 0.698 in the trial cohort and 0.567 in the clinical cohort (both P<0.0001). Known-groups validity indicated significant differences in BHQ scores stratified by baseline Bronchiectasis Severity Index. BHQ scores correlated modestly with both FEV1% predicted and exacerbation frequency within the previous year. In the trial cohort, BHQ demonstrated excellent internal consistency (Cronbach's alpha: 0.893) and test-retest reliability (intraclass correlation coefficient: 0.853). An 8-point improvement in QoL-B-RSS corresponded to a mean increase of 5.49 points in BHQ scores after 4-week treatment. The MCID for BHQ was consistently 3 points.</p><p><strong>Conclusions: </strong>The BHQ (MCID: 3 points) represents a clinically meaningful tool for evaluating therapeutic intervention outcomes and patient-centered outcomes in patients with bronchiectasis.</p>\",\"PeriodicalId\":93876,\"journal\":{\"name\":\"Annals of the American Thoracic Society\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of the American Thoracic Society\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1513/AnnalsATS.202407-751OC\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the American Thoracic Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1513/AnnalsATS.202407-751OC","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Psychometric Validation and Determination of the Minimal Clinically Important Difference for Bronchiectasis Health Questionnaire in Adults with Bronchiectasis.
Rationale: The Bronchiectasis Health Questionnaire (BHQ) is a concise, self-administered and disease-specific instrument for measuring health-related quality-of-life (HRQoL) in bronchiectasis.
Objectives: To investigate the psychometric properties of simplified Mandarin BHQ and determine the minimum clinically important difference (MCID) as a reliable clinical endpoint for assessing the efficacy of bronchiectasis treatments.
Methods: A longitudinal, randomized controlled trial cohort of 357 patients treated with tobramycin inhalation solution or saline inhalation for Pseudomonas aeruginosa infection, along with a cross-sectional observational cohort including 436 patients with bronchiectasis were analyzed. Psychometric analyses encompassed convergent validity, known-groups validity, internal consistency, test-retest reliability, and responsiveness. Both anchor-based and distribution-based approaches were utilized to calculate the MCID for therapeutic response.
Results: There were significant positive correlations between BHQ scores and the Quality of Life - Bronchiectasis Respiratory Symptom Scale (QoL-B-RSS), with correlation coefficient 0.698 in the trial cohort and 0.567 in the clinical cohort (both P<0.0001). Known-groups validity indicated significant differences in BHQ scores stratified by baseline Bronchiectasis Severity Index. BHQ scores correlated modestly with both FEV1% predicted and exacerbation frequency within the previous year. In the trial cohort, BHQ demonstrated excellent internal consistency (Cronbach's alpha: 0.893) and test-retest reliability (intraclass correlation coefficient: 0.853). An 8-point improvement in QoL-B-RSS corresponded to a mean increase of 5.49 points in BHQ scores after 4-week treatment. The MCID for BHQ was consistently 3 points.
Conclusions: The BHQ (MCID: 3 points) represents a clinically meaningful tool for evaluating therapeutic intervention outcomes and patient-centered outcomes in patients with bronchiectasis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
